Andrew Hollman Meyer - 21 Apr 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
21 Apr 2025
Net transactions value
-$85,984
Form type
4
Filing time
23 Apr 2025, 20:00:05 UTC
Previous filing
05 Mar 2025
Next filing
02 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Options Exercise $14,036 +3,334 +4.1% $4.21 85,473 21 Apr 2025 Direct
transaction JANX Common Stock Sale $100,020 -3,334 -3.9% $30.00 82,139 21 Apr 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Options Exercise $0 -3,334 -3.5% $0.000000 90,665 21 Apr 2025 Common Stock 3,334 $4.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
F2 Immediately exercisable.